Trump's Drug Pricing Plans On Slow Walk? HHS To Solicit Comment On Policies
Executive Summary
No big policy implementation expected to be announced during president's speech planned for next week. HHS will continue to gather feedback on various approaches to lowering drug pricing.
You may also be interested in...
A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?
US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.
A US Drug Pricing Rebellion Looms, Analyst Says
Wells Fargo analyst David Maris warned biopharma investors that the US drug market is on a long-term trajectory toward price controls, which he characterized as an under-appreciated risk for the sector, ahead of President Trump's speech on drug pricing.
A US Drug Pricing Rebellion Looms, Analyst Says
Wells Fargo analyst David Maris warned biopharma investors that the US drug market is on a long-term trajectory toward price controls, which he characterized as an under-appreciated risk for the sector, ahead of President Trump's speech on drug pricing.